Teva To Pay $1.2B In Antitrust Suit

May 31, 2015 | Teva Pharmaceutical Industries will pay $1.2 billion to settle a lawsuit in preventing the marketing of a generic drug similar to Teva’s Provigil. Provigil is produced by Teva’s subsidiary Cephalon and a number of retailers and wholesalers sued the company for preventing the marketing of their similar generic products. According to the ruling, Teva’s attempt to block the sale of generic drug similar to Provigil is a violation of US antitrust laws. Teva was founded in 1901 and is headed by CEO Erez Vigodman.